Peptide Direct Muscle Building
LebretonCMenardSAbedJMouraICCoppoRDugaveCet al
Disclosure of interest: Nothing to disclose Poster Session I - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P262 - ESOC25-1312 DISCHARGE RATES TO HOME FOLLOWING RECURRENT ISCHEMIC STROKE (IS): A REAL-WORLD DATA ANALYSIS ON THE CURRENT PATIENT JOURNEY IN THE US Mark Alberts 1 , Jenny Jiang 2 , Yan Wang 3 , Arimanda Reddy 4 , Haitham Alabsi 5 , Meg Thompson 5 , Merena Henderson 2 , Xiaoyan Li 2 , Priyanka Gaitonde 2 1 Hartford HealthCare, Hartford, United States, 2 Bristol Myers Squibb, Lawrenceville, United States, 3 Analysis Group Inc., Los Angeles, United States, 4 Mu-Sigma, Chicago, United States, 5 Johnson & Johnson, Raritan, United States Background and Aims: A significant proportion of IS patients experience recurrent IS within five years
5-Amino-1MQ: enzymatic pathway modulation SLU-PP-332: experimental metabolic regulation HGH Fragment: signalling and lipid pathways Quality and formulation Each batch is supplied as a refined powder to maintain stability and ensure consistent research results across experiments
